운동과 전립선 비대증/하부요로증상의 연관성

키워드

참고문헌 (64)

1. Hills W, "Manopause and andropause", Total Health, 11, pp.33~34 (2000)
2. Rosen RC, "Sexual dysfunction and lower urinary tract symptoms(LUTS)associated with benign prostatic hyperplasia(BPH)", European Urology, 47, pp.824~837 (2005)
3. Raheem OA, "Associations of obesity, physical activity and diet with benign prostatic hyperplasia and lower urinary tract symptoms", Curr Opin Urol, 24(1), pp.10~14 (2014)
4. Shier D, "Anatomy and physiology", Life Science (2015)
5. Willis D, "Taming the overgrown prostate", Am J Nurs, 92(2), pp.34~40 (1992)
6. 김정선, "전립선비대증환자의 건강 관련 삶의 질 영향 요인", Journal of Korean Academy of Nursing, 40(2), pp.287~297 (2010), 한국간호과학회
7. Kim MS, "Affecting factors to the quality of life in patients with benign prostatic hyperplasia", pp.2008
8. 김미영, "과민성방광증후군 여성의 증상 심각도, 스트레스 및건강 관련 삶의 질", 여성건강간호학회지, 19(4), pp.295~305 (2013), 한국여성건강간호학회
9. Ho CK, "Estrongen and androgen signaling in the pathogenesis of BPH", Urology, 8(1), pp.29~41 (2011)
10. Sea J, "Review of exercise and the risk of benign prostatic hyperplasia", Phys Sportsmed, 37(4), pp.75~83 (2009)
11. Jae Seung Paick, "Impacts of the Quinazoline-Based Alpha1-Antagonist, Terazosin, and of the Sulfonamide Derivative, Tamsulosin, on Serum Prostate-Specific Antigen and Prostate Volume", Journal of Korean Medical Science, 23(3), pp.509~513 (2008), 대한의학회
12. Johnson TM 2nd, "Changes in nocturia from medical treatment of benign prostatic hyperplasia : secondary analysis of the department of veterans affairs cooperative study trial", J Urol, 170, pp.145~148 (2003)
13. Peng CC, "Action mechanism of Ginkgo biloba leaf extract intervened by exercise therapy in treatment of bening prostate hyperplasia", Evid Based Complement Alternat Med, 2013, pp.408734~ (2013)
14. Carson C 3rd, "The role of dihydrotestosterone in benign prostatic hyperplasia", Urology, 61(4 Suppl 1), pp.2~7 (2003)
15. Ziada A, "Benign prostatic hyperplasia:an overview", Urology, 53(Sup 3A), pp.1~6 (1999)
16. Caine M., "The present role of α-adrenergic blockers in the treatment of benign prostatic hypertrophy", J. urol, 136(1), pp.1~4 (1986)
17. Roehrborn CG, "Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia(BPH)by baseline characteristics : 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin(CombAT)trial", BJU Int, 107(6), pp.946~954 (2011)
18. Thomas JA, "Diet, micronutrients, and the prostate gland", Nutr Rev, 57(4), pp.95~103 (1999)
19. Warburton DE, "Health benefits of physical activity : the evidence", CMAJ, 174, pp.801~809 (2006)
20. Platz EA, "Physical activity and benign prostatic hyperplasia", Arch Intern Med, 158(21), pp.2349~2356 (1998)
21. St. Sauver JL, "Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia", Am J Epidemiolo, 164(8), pp.760~768 (2006)
22. Abramson JL, "Relationship between physical activity and inflammation among apprently healthy middle-aged and older US adults", Arch Intern Med, 162(11), pp.1286~1292 (2002)
23. Vesely S, "Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms", Scand J Urol Nephrol, 37(4), pp.322~328 (2003)
24. Kristal AR, "Race", ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia : results from the prostate cancer prevention trial, 2007, pp.177(4), 1395~1400
25. Dal Maso L, "Lifetime occupatioal and recreational physical activity and risk of benign prostatic hyperplasia", Int J Cancer, 118(10), pp.2632~2635 (2006)
26. Lacey JV, "Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China", Int J Ejpidemiol, 30(2), pp.341~349 (2001)
27. "Control study" (2018)[URL]
28. "Odds ratio" (2018)[URL]
29. "Prospective cohort study" (2018)[URL]
30. Meigs JB, "Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men", J Clin Epidemiol, 54, pp.935~944 (2001)
31. Williams PT, "Effects of running distance and performance on incident benign prostatic hyperplasia", Med Sci Sports Exerc, 40(1), pp.1733~1739 (2008)
32. Prezioso D, "Lifestyle in patients with LUTS suggestive of BPH", Eur Urol, 40(supple 1), pp.9~12 (2001)
33. Rohrmann S, "Association of cigarette smoking, alcohol consumption and physical activity with lower urinary tract symptoms in older American men : findings from the third National Health and Nutrition Examination Survey", BJU Int, 96, pp.77~82 (2005)
34. Lagiou A, "Occupational physical activity in relation with prostate cancer and benign prostatic hyperplasia", Eur J Cancer Prev, 17(4), pp.336~339 (2008)
35. Wolin KY, "Physical activity and benign prostatic hyperplasia-related outcomes and nocturia", Med Sci Sports Exerc, 47(3), pp.581~592 (2014)
36. 이호원, "The Study About Physical Activity for Subjects With Prevention of Benign Prostate Hyperplasia", International Neurourology Journal, 18(3), pp.155~162 (2014), 대한배뇨장애요실금학회
37. Hong J, "Risk factors for benign prostatic hyperplasia in South Korean men", Urol Int, 76(1), pp.11~19 (2006)
38. Joseph MA, "Risk factors for lower urinary tract symptoms in a population-based sample of African-American men", Am J Epidemiol, 157(10), pp.906~914 (2003)
39. De Nunzio C, "The correlation between metabolic syndrome and prostatic diseases", Eur Urol, 61, pp.560~570 (2012)
40. Furuya S, "Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy", J Urol, 128(4), pp.836~839 (1982)
41. McVary KT, "Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia", J Urol, 174(4 pt 1), pp.1327~1433 (2005)
42. Troisi RJ, "Relation of obesity and diet to sympathetic nervous system activity", Hypertension, 17(5), pp.669~677 (1991)
43. Eikelis N, "Interactions between leptin and the human sympathetic nervous system", Hypertension, 41(5), pp.1072~1079 (2003)
44. Mueller PJ, "Exercise training and sympathetic nervous system activity : evidence for physical activity dependent neural plasticity", Eclin Exp Pharmacol Physiol, 34(4), pp.377~384 (2007)
45. Giovannucci E, "Obesity and benign prostatic hyperplasia", Am J Epidemiol, 140(11), pp.989~1002 (1994)
46. Hammarsten J, "Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia", Prostate Cancer Prostatic Dis, 1(3), pp.157~162 (1998)
47. Hammarsten J, "Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia", Prostate Cancer Prostatic Dis, 12(2), pp.160~165 (2009)
48. Ozden C, "The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia", Eur Urol, 51(1), pp.199~203 (2007)
49. Neuhouser ML, "Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial", Prostate, 68(13), pp.1477~1486 (2008)
50. Andriole G, "Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia", J Urol, 172(4 Pt 1), pp.1399~1403 (2004)
51. Roehrborn CG, "Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2(dutasteride)in men with benign prostatic hyperplasia", Urology, 60(3), pp.434~441 (2002)
52. Hackney AC, "Testosterone and endurance exercise : development of the"exercise-hypogonadal male condition"", Acta Phsiol Hung, 92(2), pp.121~137 (2005)
53. Hackney AC, "Basal testicular testosterone production in endurance-trained men is suppressed", Eur J Appl Physiol, 89(2), pp.198~201 (2003)
54. Schenk JM, "Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia : results from the prostate cancer prevention trial", Am J Epidemiol, 171, pp.571~582 (2010)
55. St. Sauver JL, "Statin use and decreased risk of bening prostatic enlargement and lower urinary tract symptoms", BJU Int, 107, pp.443~450 (2011)
56. Schenk JM, "Indications for and use of nonsteroidal anti inflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia : results from the prostate cancer prevention trial", Am J Peidemiol, 176, pp.156~163 (2012)
57. Sutcliffe S, "Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the prostate, lung, colorectal, and ovarian cancer screening trial", BJU Int, 110, pp.1050~1059 (2012)
58. 최우석, "Is High-Sensitivity C-Reactive Protein Associated with Lower Urinary Tract Symptoms in Aging Men? Results from the Hallym Aging Study", Investigative and Clinical Urology, 53(5), pp.335~341 (2012), 대한비뇨의학회[DOI]
59. Chang IH, "A possible relationship between testosterone and lower urinary tract symptoms in men", J Urol, 182, pp.215~220 (2009)
60. Nickel JC, "The relationship between prostate inflammation and lower urinary tract symptoms : examination of baseline data from the REDUCE trial", Eur Urol, 54(6), pp.1379~1384 (2008)
61. Cheng Y, "Therapeutic targeting of autophagy in disease : Biology and pharmacology", Pharmacol Rev, 65, pp.1162~1197 (2013)
62. Liu C, "Roles of autophagy-related genes Beclin-1 and LC3 in the development and progression of prostatic cancer and benign prostatic hyperplasia", Biomed Rep, 1, pp.855~860 (2013)
63. Lesovaya EA, "Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostatic hyperplasia in rats", Oncotarget, 6, pp.9718~9727 (2015)
64. Ju JS, "Autophagy plays a role in skeletal muscle mitochondrial biogenesis in an endurance exercisetrained condition", J Physiol Sci, 66, pp.417~430 (2016)

관련 논문AI추천